Valeo Pharma (VPH.C) has gotten their their Hesperco flavonoid formulation on shelves at over 300 stores under the Loblaws brand, including Loblaws, Dominion, Zehs, Fortinios, Your Independent Grocer and Superstore.
Getting these products onto shelves in big retailers like those under the Loblaws umbrella is really the gold standard. The George Weston Corporation, which owns Loblaws, itself is Canada-wide, which makes this product’s next step easy to discover if it flies off shelves.
“We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied,” said Steve Saviuk, CEO of Valeo.
Valeo Pharma’s focus is on getting prescription products associated with Respirology, Neurodegenerative diseases, Oncology and other specialty products on shelves with the widest distribution net possible. Their headquarters is in Kirkland, Quebec, and they have the full capability and infrastructure to register and manage their portfolio through all stages of commercialization.
The company’s recent collaboration with Ingenew Pharma for development, manufacturing of commercialization of Hesperco has also yielded some fruit. Ingenew has discovered processes regarding how to use Hesperidin as it pertains to COVID-19, and has subsequently teamed up with the Montreal Heart Institute to perform a randomized, double-blind, placebo-controlled clinical trial.
“In the current circumstances, it is timely that this placebo-controlled study confirms hesperidin’s safety and potential benefits for the management of COVID-19 symptoms. We share the enthusiasm of the clinical investigators who performed the study and are considering follow-on studies to further support the use of this product to support the immune system in various medical conditions,” said Mr. Pierre Laurin, MSc Pharm, president of Ingenew Pharma
The results have been collected in a report called “Fourteen-days Evolution of COVID-19 Symptoms During the Third Wave in Non-vaccinated Subjects and Effects of Hesperidin Therapy: A randomized, double-blinded, placebo-controlled study” which was submitted for publication.
—Joseph Morton
